Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.66 |
| ▸ | NCF1 | P14598 | 1/20 | 0.57 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30210360 | 1.00 | NR4A2 (0.66) | NR4A2NCF1SOS2MAPTKDM4E | |
| Bromide SCHEMBL5989384 | 0.98 | NR4A2 (0.63) | NR4A2NCF1SOS2MAPTKDM4E | |
| SCHEMBL30044428 | 0.83 | NR4A2 (0.66) | NR4A2NCF1SOS2MAPTKDM4E | |
| SCHEMBL3073397 | 0.83 | NR4A2 (0.66) | NR4A2NCF1SOS2MAPTKDM4E | |
| SCHEMBL25398078 | 0.79 | MAPT (0.46) | NR4A2NCF1MAPTKDM4EHSP90AA1 | |
| SCHEMBL3649184 | 0.79 | NR4A2 (0.52) | NR4A2NCF1SOS2MAPTKDM4E | |
| SCHEMBL11159915 | 0.79 | SLC22A12 (0.48) | NR4A2NCF1MAPTKDM4EHSP90AA1 | |
| SCHEMBL17693565 | 0.79 | MAPT (0.46) | NR4A2NCF1MAPTKDM4EHSP90AA1 | |
| SCHEMBL4644505 | 0.79 | SMN1; SMN2 (0.51) | NR4A2MAPTKDM4EHSP90AA1HSP90AB1 | |
| SCHEMBL14242727 | 0.79 | NR4A2 (0.61) | NR4A2NCF1SOS2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104203279-B | Treatment of brain cancer | 阿雷生物药品公司 | 2018-10-30 | — | — | CN | claimed |
| CN-105061410-B | A kind of Afatinib and its preparation method and application | 江苏红豆杉药业有限公司 | 2018-04-20 | — | — | CN | claimed |
| EP-0614915-B1 | Polymer scale preventive agent | SHINETSU CHEMICAL CO (JP) | 1998-06-24 | — | — | EP | claimed |
| EP-4050005-B1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-3380469-B1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-109381469-B | Novel application of quinazoline derivative tyrosine kinase inhibitor | 山东轩竹医药科技有限公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-106752954-B | CCB high sealing water-repellent paint | 广东鼎新高新科技股份有限公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109223791-A | The treatment of the cancer of the brain | 阿雷生物药品公司 | 2019-01-18 | — | — | CN | disclosed |
| CN-104203279-B | Treatment of brain cancer | 阿雷生物药品公司 | 2018-10-30 | — | — | CN | disclosed |
| CN-105061410-B | A kind of Afatinib and its preparation method and application | 江苏红豆杉药业有限公司 | 2018-04-20 | — | — | CN | disclosed |
| CN-107556295-A | Quinazoline derivant and preparation method thereof | 正大天晴药业集团股份有限公司 | 2018-01-09 | — | — | CN | disclosed |
| US-20050009815-A1 | 4-Aminoquinoline compounds | DEVITA ROBERT J (US) | 2005-01-13 | — | — | US | disclosed |
| US-6815447-B2 | 6-N-(2-AMINO-PYRIMIDIN-4-YL)QUINOLINE-6-AMINE DERIVATIVES; ANALGESICS | ASTRAZENECA AB (SE) | 2004-11-09 | — | — | US | disclosed |
| EP-1451156-A1 | 4-AMINOQUINOLINE COMPOUNDS | Merck & Co., Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045920-A1 | 4-AMINOQUINOLINE COMPOUNDS | MERCK & CO., INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| US-20030055087-A1 | Amide derivatives and nociceptin antagonists | JAPAN TOBACCO INC. | 2003-03-20 | — | — | US | disclosed |
| US-6410561-B1 | ANALGESICS | JAPAN TOBACCO INC. (JP) | 2002-06-25 | — | — | US | disclosed |
| EP-1072263-A1 | AMIDE DERIVATIVES AND NOCICEPTIN ANTAGONISTS | JAPAN TOBACCO INC. (JP) | 2001-01-31 | — | — | EP | disclosed |
| US-5919776-A | ANTIINFLAMMATORY AGENT; AUTOIMMUNE DISEASE | MERCK & CO., INC. (US) | 1999-07-06 | — | — | US | disclosed |
| WO-1998027815-A1 | SUBSTITUTED AMINOQUINOLINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055087-A1 | Amide derivatives and nociceptin antagonists | OPRL1, OPRD1, OPRK1 | NR4A2 165/4885NCF1 785/4885SOS2 3904/4885 |
| US-20050009815-A1 | 4-Aminoquinoline compounds | MCHR1, MCHR2, MC5R | NR4A2 2037/4885NCF1 4005/4885SOS2 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.